anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a novel platelet freeze-drying treating fluid. The fluid is composed of two parts: (1) a platelet freeze-drying pretreatment liquid, which is prepared by adding mycose and PGE1 into a basic buffer liquid; (2) a platelet freeze-drying buffer liquid, which is prepared by adding blood plasma into a freeze-drying pretreatment liquid. Preferably 30%v/v-40%v/v blood plasma is adopted to replace human serum albumin, a good effect is achieved, and the blood plasma is taken as the platelet protein protective agent to replace the pricy albumin and is economic. The osmotic pressure of the pretreatment liquid is 311.6 mOsm, is similar to the blood plasma osmotic pressure, and thus will not generate adverse effect on platelet. The weight concentration of the freeze-drying buffer liquid is 29%w/v, and the obtained freeze-dried platelet has a qualified appearance. The freeze-dried platelet can be stably preserved at a room temperature for at least 6 months, and the platelet can be used to prepare hemostatic or platelet products used in operation.
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components ( see Contraindications (4)). In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.
Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. In Group 4, one lot of BioThrax® vaccine will be administered, per the study visit schedule.
Chronic hepatitis B virus (HBV) infection is a leading cause of liver associated morbidity and mortality. Currently available first-line therapies for treatment of chronic hepatitis B include pegylated interferon-alpha and the nucleos(t)ide analogues (NUCs) entecavir and tenofovir. These were shown to effectively suppress viral replication, but their ability to induce durable off-treatment response is limited to a small subset of patients. Combination treatment with peginterferon and NUCs has been attempted in several randomized controlled trials, with no apparent advantage over either agent given alone. In these studies however, treatment with peginterferon was initiated either simultaneously or shortly after NUCs administration. The efficacy of peginterferon following long-term viral suppression with NUCs was only tested in one small pilot study, nevertheless showing 60% hepatitis B s antigen (HBsAg) loss rate.

The underlying mechanisms responsible for improved efficacy of peginterferon in this setting are unknown and warrant further investigation. In this single arm study we propose to evaluate the efficacy and mechanisms associated with response to peginterferon add-on therapy following a minimum of 192 weeks of viral suppression induced by NUCs in a group of chronic HBV infected patients. Sixty patients with either hepatitis B e antigen (HBeAg) positive (n=30) or negative (n=30) chronic HBV infection will be enrolled to this study. After medical evaluation and pretreatment liver biopsy, treatment with subcutaneous injections of pegylated interferon alpha-2a 180 g per week will be given for a total of 24 weeks, followed by an off-treatment evaluation period of 48 weeks. A second liver biopsy will be performed six hours following the first peginterferon injection. Primary end-point for this study will be the change in interferon-stimulated-genes response before and after first interferon injection in responders versus non-responders to treatment. The responsiveness to IFN-based therapy of treatment responders vs nonresponders will additionally be evaluated by studying intrahepatic and peripheral blood natural killer cells. The study will also assess HBeAg and HBsAg loss and seroconversion rates in comparison to historical controls treated with either peginterferon or NUCs monotherapy. Finally, we will assess whether treatment responders develop an HBV-specific T cell response similar in quantity and quality to that of patients who spontaneously resolve HBV infection.
Anorexia nervosa (AN) is a severe psychiatric disorder. However, neurobiological models and interventions to explain and treat the core characteristics of food restriction, feeling fat, and body size overestimation are lacking. While research has made progress in understanding brain function involved in AN pathophysiology, translating those results into biological therapies has been challenging. Studies have suggested that metabolic factors contribute to developing and maintaining AN pathophysiology. Specifically, brain glucose utilization and metabolism may be altered in AN, interfere with brain energy homeostasis, and contribute to illness development and maintenance. A small study indicated that ketosis might be therapeutic for AN core behaviors such as eating and shape concerns. In this application, the investigator will study individuals weight recovered from AN, establish biological targets as diet-related metabolic markers for AN (R61 phase), and replicate and link those targets to AN-specific behaviors (R33 phase). The weight recovered AN group will also be compared with a healthy control sample. The R61 Phase Specific Aim of the project is to establish target engagement for a therapeutic ketogenic diet (TKD) in AN after weight recovery and establish safety and tolerability. It is hypothesized that TKD will be associated with reduced brain glucose metabolism using \[18F\]fluorodeoxyglucose (\[18F\]FDG) and positron emission tomography (PET) (target engagement). Higher blood ketosis levels will be associated with a more significant reduction of the brain \[18F\]FDG glucose metabolism rate (dose dependency). It is hypothesized that TKD will be well tolerated, that participants will remain within the normal weight range (tolerability), and that study participants will be able to adhere to TKD as indicated by regular blood ketosis measurements (treatment fidelity). There will be an initial indication that TKD and associated biological measures correlate with behavioral measures derived from eating disorder-specific assessments.
The Chinese medicine group used Guizhi-Shaoyao-Zhimu decoction (GZSD) as their medical intervention. The GZSD samples were made and packed by Sun Ten Pharmaceutical Co. Ltd., a firm that meets the requirements of the good manufacturing practice (GMP) certification in Taiwan. Every 4g of concentrated GZSD was sealed in an isolated paper drug bag.
AIMS: Despite clear guideline recommendations for initiating four drug classes in all patients with heart failure (HF) with reduced ejection fraction (HFrEF) and the availability of rapid titration schemes, information on real-world implementation lags behind. Closely following the 2021 ESC HF guidelines and 2023 focused update, the TITRATE-HF study started to prospectively investigate the use, sequencing, and titration of guideline-directed medical therapy (GDMT) in HF patients, including the identification of implementation barriers.
METHODS AND RESULTS: TITRATE-HF is an ongoing long-term HF registry conducted in the Netherlands. Overall, 4288 patients from 48 hospitals were included. Among these patients, 1732 presented with de novo, 2240 with chronic, and 316 with worsening HF. The median age was 71 years (interquartile range [IQR] 63-78), 29% were female, and median ejection fraction was 35% (IQR 25-40). In total, 44% of chronic and worsening HFrEF patients were prescribed quadruple therapy. However, only 1% of HFrEF patients achieved target dose for all drug classes. In addition, quadruple therapy was more often prescribed to patients treated in a dedicated HF outpatient clinic as compared to a general cardiology outpatient clinic. In each GDMT drug class, 19% to 36% of non-use in HFrEF patients was related to side-effects, intolerances, or contraindications. In the de novo HF cohort, 49% of patients already used one or more GDMT drug classes for other indications than HF.
CONCLUSION: This first analysis of the TITRATE-HF study reports relatively high use of GDMT in a contemporary HF cohort, while still showing room for improvement regarding quadruple therapy. Importantly, the use and dose of GDMT were suboptimal, with the reasons often remaining unclear. This underscores the urgency for further optimization of GDMT and implementation strategies within HF management.
Does the present invention provide a kind of nucleotide sequence for arch insect infection prevention, containing being selected from following nucleotide sequence: 1) SEQ? ID? 724-shown in No.3 the 1470th nucleotide sequence; And/or SEQ? ID? 724-shown in No.1 the 2472nd nucleotide sequence; 2) with 1) shown in the nucleotide sequence of nucleotide sequence complementation; 3) to above-mentioned 1) or 2) shown in nucleotide sequence carries out the replacement of one or more base, disappearance, interpolation are modified nucleotide sequence. The pVAX-CDPK1 of the present invention can the infection of prevention and corntrol toxoplasma gondii animal model (Kunming mouse) effectively, simultaneously, pVAX-IL21-IL15 be not only used alone can the infection of prevention and corntrol toxoplasma gondii effectively, and can effectively promote the immune effect of vaccine pVAX-CDPK1 as Cytokine adjuvant.
FIELD: cosmetology.SUBSTANCE: group of inventions relates to a cosmetic product. The cosmetic product contains a solvent containing water, zinc oxide powder, which is present in the solvent and carries a positive charge on a surface, polyelectrolyte, which is a source of ionic polymer, which has an anionic functional group, and salt, which is a source of a polyvalent ion, which carries a positive charge, where powder and ionic polymer are electrostatically and/or ionically bound to each other, ionic polymer and polyvalent ion are electrostatically and/or ionically bound to each other, powder forms weak flocculation by means of ionic polymer and polyvalent ion; the powder content is 10-50 wt.%; the polyelectrolyte content is 0.005-0.5 wt. pt. relatively to 1 wt. pt. of powder; the salt content is 0.05-5 wt. pt. relatively to 1 wt. pt. of polyelectrolyte; ionic polymer is a polyacrylate ion and/or hexametaphosphate ion; the polyvalent ion is a magnesium ion and/or calcium ion; and the molecular weight of ionic polymer is 3000-15000. Another option of the cosmetic product and methods for producing a cosmetic product are also disclosed.EFFECT: group of inventions provides a composition, in which powder is hardly hardened and is easy to disperse.12 cl, 6 dwg, 3 tbl, 4 ex
C-Reactive Protein (CRP) and Serum Amyloid A (SAA) are indicators of inflammatory disease activity that are elevated in patients with CAPS. Elevated SAA has been associated with the development of systemic amyloidosis in patients with CAPS. Compared to placebo, treatment with ARCALYST resulted in sustained reductions from baseline in mean serum CRP and SAA to normal levels during the clinical trial. ARCALYST also normalized mean SAA from elevated levels.

CRP is also an indicator of inflammation in DIRA. Maintenance of CRP reduction was observed in a clinical trial of pediatric patients with DIRA [see Clinical Studies (14.2)].

CRP is also a recognized indicator of inflammation in pericarditis. Treatment with rilonacept was observed in a clinical trial with RP to be associated with resolution of acute pericarditis episodes, including rapid and sustained reduction in CRP, with a median time to normalization of 7 days [see Clinical Studies (14.3)].
Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
At Marmur Medical, subjects will be recruited and consented prior to any study evaluations or procedures; if subjects meet the inclusion/exclusion criteria, participants will be enrolled into this study. Informed consent will clearly say the use of hyaluronic acid filler for the treatment of dorsal finger volume loss is investigational. Subjects will also be compensated for their visits (initial and six follow-ups totalling seven visits). Pre and post treatment photographs will be taken. Subjects will be given lidocaine cream to apply to the area of injection for temporary numbing effect prior to injection (10-15 minutes). Ice packs will also be applied to the area temporarily for numbing effect just prior to injection. The patient's fingers will be injected with 0.5-2.0 mL of hyaluronic acid total at the level of the sub-dermal plane. The injected filler will be molded as needed to optimize the correction of the fingers. Syringes used and amount injected into each finger, as well as the total per hand, will be documented to the 0.1 mL increment (e.g. 3.4 mL). The expected volume needed is 1-2 syringes per subject initially. On Day 14, subjects will return for evaluation and possible touch-up of injectable hyaluronic acid filler if needed (at the injector's discretion). The expected volume needed may be 1-2 syringes per subject for touch-up.

The subjects will return for follow-up at all time-points as follows: day 14 (+/- touch-up hyaluronic acid injection if necessary), 6 weeks, 3/6/9/12 months. The patient and investigator(s) will assess the volume enhancement in the fingers. Subjects will be asked to rate their level of satisfaction with the treatment at follow-up visits (Global Satisfaction Assessment, Natural Look/Feel Scale). In addition, at the initial visit, subjects will be given a 30 day diary to fill out that will evaluate for symptomology after injection (pain, bruising, swelling, redness, sensitivity/tenderness, itching, lumps/bump development, temporary numbness, signs of vascular compromise or other/open comment box). The subject diary will be collected at the 3 month follow-up visit. Statistical analysis of the data gathered will be performed by an outside statistician using tests such as Wilcoxian signed-rank test (for two observations) or Friedman's test (for more than 2 observations) using STAT, version 13. All adverse events will be recorded at every follow-up visit. These events include: redness, swelling, tenderness, nodule development under the skin and restricted range of motion. More serious adverse events include: compartment syndrome, infection at injection site, Tyndall effect, persistent granulomatous change, injection necrosis, persistent erythema with edema, and vascular occlusion causing symptoms such as pain, numbness and necrosis.
The invention discloses a novel medicine flavor health care pillow and a manufacture method thereof. The medicine flavor health care pillow mainly consists of a pillow sleeve and a pillow core, wherein the pillow core is in a cylindrical shape, in addition, rice and wheat straw sections and cassia seeds with the weight part ratio of 1/4 are filled inside the pillow core, and wormwood, sandal and camphor wood are also contained inside the pillow core. The rice and wheat straw sections in the invention are soft, the cassia seeds are hard particles, the rice and wheat straw sections and the cassia seeds are mixed to obtain materials with proper hardness. At the same time, the cassia seeds have the functions of calming the nerves to concentrate the attention, calming the liver to improve the eyesight and the like, have the certain relief function on patients with light insomnia, psychentonia and the like, can promote the sleeping, and has the effect of improving the sleeping quality. The sandal in the invention has the sterilization and disinfection effect, and has the functions of calming the nerves to preserve the health, assisting the deep thought and refreshing the mind to set aside all worries. The novel medicine flavor health care pillow of the invention is designed into the cylindrical shape, and can effectively reduce the occurrence rate of stiff neck.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use olanzapine tablets for a condition for which it was not prescribed. Do not give olanzapine tablets to other people, even if they have the same condition. It may harm them. 

This Medication Guide summarizes the most important information about olanzapine tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about olanzapine tablets that was written for healthcare professionals. For more information about olanzapine tablets call 1-888-375-3784.
BACKGROUND AND AIMS: Hyperuricemia frequently accompanies dyslipidemia, yet the precise mechanism remains elusive. Leveraging cellular metabolomics analyses, this research probes the potential mechanisms wherein hyperuricemia provokes endothelial cell abnormalities, inducing disordered bile metabolism and resultant lipid anomalies.
METHODS AND RESULTS: We aimed to identify the differential metabolite associated with lipid metabolism through adopting metabolomics approach, and thereafter adequately validating its protective function on HUVECs by using diverse assays to measure cellular viability, reactive oxygen species, migration potential, apoptosis and gene and protein levels of inflammatory factors. Taurochenodeoxycholic acid (TCDCA) (the differential metabolite of HUVECs) and the TCDCA-involved primary bile acid synthesis pathway were found to be negatively correlated with high UA levels based on the results of metabolomics analysis. It was noted that compared to the outcomes observed in UA-treated HUVECs, TCDCA could protect against UA-induced cellular damage and oxidative stress, increase proliferation as well as migration, and decreases apoptosis. In addition, it was observed that TCDCA might protect HUVECs by inhibiting UA-induced p38 mitogen-activated protein kinase/nuclear factor kappa-B p65 (p38MAPK/NF-κB p65) pathway gene and protein levels, as well as the levels of downstream inflammatory factors.
CONCLUSION: The pathogenesis of hyperuricemia accompanying dyslipidemia may involve high uric acid levels eliciting inflammatory reactions and cellular damage in human umbilical vein endothelial cells (HUVECs), mediated through the p38MAPK/NF-κB signaling pathway, subsequently impinging on cellular bile acid synthesis and reducing bile acid production.
INTRODUCTION: Urogenital hiatus enlargement is a critical factor associated with prolapse and operative failure. This study of the perineal complex was performed to understand how interactions among its three structures: the levator ani, perineal membrane, and perineal body-united by the vaginal fascia-work to maintain urogenital hiatus closure.
METHODS: Magnetic resonance images from 30 healthy nulliparous women with 3D reconstruction of selected subjects were used to establish overall geometry. Connection points and lines of action were based on perineal dissection in 10 female cadavers (aged 22-86 years), cross sections of 4 female cadavers (aged 14-35 years), and histological sections (cadavers aged 16 and 21 years).
RESULTS: The perineal membrane originates laterally from the ventral two thirds of the ischiopubic rami and attaches medially to the perineal body and vaginal wall. The levator ani attaches to the perineal membrane's cranial surface, vaginal fascia, and the perineal body. The levator line of action in 3D reconstruction is oriented so that the levator pulls the medial perineal membrane cranio-ventrally. In cadavers, simulated levator contraction and relaxation along this vector changes the length of the membrane and the antero-posterior diameter of the urogenital hiatus. Loss of the connection of the left and right perineal membranes through the perineal body results in diastasis of the levator and a widened hiatus, as well as a downward rotation of the perineal membrane.
CONCLUSION: Interconnections involving the levator ani muscles, perineal membrane, perineal body, and vaginal fascia form the perineal complex surrounding the urogenital hiatus in an arrangement that maintains hiatal closure.
CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .
Cereblon/CRBN is a substrate-recognition component of the Cullin4A-DDB1-Roc1 E3 ubiquitin ligase complex. Destabilizing mutations in the human CRBN gene cause a form of autosomal recessive non-syndromic intellectual disability (ARNSID) that is modelled by knocking-out the mouse Crbn gene. A reduction in excitatory neurotransmission has been proposed as an underlying mechanism of the disease. However, the precise factors eliciting this impairment remain mostly unknown. Here we report that CRBN molecules selectively located on glutamatergic neurons are necessary for proper memory function. Combining various in vivo approaches, we show that the cannabinoid CB1 receptor (CB1R), a key suppressor of synaptic transmission, is overactivated in CRBN deficiency-linked ARNSID mouse models, and that the memory deficits observed in these animals can be rescued by acute CB1R-selective pharmacological antagonism. Molecular studies demonstrated that CRBN interacts physically with CB1R and impairs the CB1R-Gi/o-cAMP-PKA pathway in a ubiquitin ligase-independent manner. Taken together, these findings unveil that CB1R overactivation is a driving mechanism of CRBN deficiency-linked ARNSID and anticipate that the antagonism of CB1R could constitute a new therapy for this orphan disease.
Hair cleansing conditioners which contain, in relation to the weight of the total composition, 0.0001 to 10 wt. % of a cationic 3-acrylamidopropyl trimethylammonium salt homopolymer and 0.01 to 20 wt. % of at least one non-ionic surfactant and/or at least one amphoteric surfactant. The polymer is preferably poly(3-acrylamidopropyl)trimethylammonium chloride. The non-ionic surfactant is preferably an alkyl(oligo)glycoside, such as lauryl glucoside, coco glucoside, decyl glucoside, and/or the amphoteric surfactant is preferably selected from sodium cocoampho(di)acetate or cocamidopropyl betaine. The composition is preferably substantially free from anionic surfactants. The composition may be present in the form of an aerosol mousse and may comprise a propellant. The composition may comprise a protein hydrolysate. The composition may be applied to hair which is preferably wet, messaged in and then rinsed out after a reaction time.